|Toxiciy Grade:||4||City/State/Province:||Philadelphia, PA|
|Treatments:||Chemotherapy, Immunotherapy||Hospital:||Fox Chase Cancer Center|
This phase II study involved 31 patients with low-grade non-Hodgkin's lymphoma. The median patient age was 62 years and 15 were male.
Patients were treated with the chemotherapy agent fludarabine and the immunotherapy agent interferon-alpha (IFN), which stimulates the immune system to attack cancer cells.
The most severe adverse events were of grade 4 and included anemia, lymphopenia, and thrombocytopenia. Fever, fatigue, and nausea were also reported.
The median overall survival was 60.8 months.
This study was partially supported by the pharmaceutical company Roche.
Correspondence: Dr. Mitchell R. Smith; email: email@example.com